HIGHLIGHTS
- who: Randomized Open Investigation Determining and colleagues from the Hofstra/Northwell, Hempstead, USA Internal Medicine/Pulmonary and Critical Care, University of Kansas Medical have published the paper: Review began 10/23/2022 Review ended 10/27/2022 Published 11/04/2022 u00a9 Copyright, in the Journal: (JOURNAL) of March/19,/2021
- what: In patients with COVID-19 and hypoxemia, the use of weight-based dexamethasone dosing was not superior to dexamethasone 6 mg in reducing all-cause mortality at 28 days.
- how: One patient from the control group withdrew consent from the study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.